AktiVax

Executive Summary

AktiVax, operating under Aktiv Medical Systems, is a Boston-based medical device company that has developed the PenPal® autoinjector platform, a gas-powered drug delivery system designed for high-viscosity biologics and large-volume doses exceeding 2.25 mL. Founded in 2021, the company targets the growing need for reliable, user-friendly delivery solutions for complex injectable therapies, partnering with pharmaceutical companies to bring their biologic drugs to market. With its platform already approved, AktiVax is positioned to capture share in the autoinjector market, particularly for high-viscosity formulations that challenge conventional devices. The company's strategy centers on licensing its technology to pharma partners, enabling rapid adoption without the risk of drug development. Given the expanding pipeline of biologic drugs requiring subcutaneous delivery, AktiVax's platform addresses a critical unmet need. However, the company faces competition from established players and must demonstrate clear differentiation to win partnerships. Its success hinges on securing commercial agreements and potentially expanding into new therapeutic areas.

Upcoming Catalysts (preview)

• Q3 2026First Commercial Partnership Announcement70% success
• Q4 2026FDA Clearance for Additional Device Configurations60% success
• TBDClinical Study Results Demonstrating User Preference or Safety50% success